Vareniclina

943 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
943
On SlideShare
0
From Embeds
0
Number of Embeds
9
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Vareniclina

  1. 1. VareniclinaAndrea Isabel Arteaga
  2. 2. Action at 42 nicotine receptor Partial agonist/antagonist Releases lower amounts of dopamine intobrain than smoke • Reduces withdrawal • Not as addictive as smokeBlocks nicotine from binding to receptor • Prevents reward of smoking
  3. 3. Mecanismo de acción
  4. 4. Efectos adversos Sleep Nausea Constipation Disturbance changes in Vomiting Gas behavior
  5. 5. Evidencia
  6. 6. Varenicline phase 2 trial CO-confirmed 4-week continuous quit rates, at week 1260 50.650 45.140 0.5 mg 2/day30 1.0 mg 2/day Placebo20 12.4100 p<0.0001
  7. 7. Varenicline clinical trial CO-confirmed 4-week continuous quit rates, at week 745 40.84035 3130 28.6 0.3 mg 1/day 25.4 1.0 mg 1/day25 1.0 mg 2/day20 13.8 Zyban 150*215 Placebo1050 p<0.05
  8. 8. Varenicline 12 semaines + si succès encore 12 semaines varenicline ou placebo80 717060 5050 12 sem + placebo40 12+12 sem3020100 Communiqué de presse du 15 nov 2005, Pfizer
  9. 9. Increased CV risk with smoking cessation drug varenicline: New meta-analysis Sources1. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated withvarenicline: a systematic review and meta-analysis. CMAJ 2011. Available at:http://www.cmaj.ca2. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011.

×